BIODEXA PHARMACEUTICALS-ADR (BDRX)
US59564R7089 - ADR
Overall BDRX gets a fundamental rating of 1 out of 10. We evaluated BDRX against 587 industry peers in the Biotechnology industry. BDRX may be in some trouble as it scores bad on both profitability and health. BDRX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BDRX had negative earnings in the past year.
In the past year BDRX has reported a negative cash flow from operations.
In the past 5 years BDRX always reported negative net income.
In the past 5 years BDRX always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -67.15%, BDRX is not doing good in the industry: 63.59% of the companies in the same industry are doing better.
BDRX has a Return On Equity of -151.33%. This is in the lower half of the industry: BDRX underperforms 66.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.15% | ||
| ROE | -151.33% | ||
| ROIC | N/A |
ROA(3y)-82.67%
ROA(5y)-101.33%
ROE(3y)-148.56%
ROE(5y)-165.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BDRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BDRX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, BDRX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -13.64, we must say that BDRX is in the distress zone and has some risk of bankruptcy.
BDRX's Altman-Z score of -13.64 is on the low side compared to the rest of the industry. BDRX is outperformed by 81.71% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that BDRX is not too dependend on debt financing.
BDRX's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. BDRX is outperformed by 61.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.64 |
ROIC/WACCN/A
WACC7.83%
2.3 Liquidity
BDRX has a Current Ratio of 1.26. This is a normal value and indicates that BDRX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.26, BDRX is not doing good in the industry: 85.98% of the companies in the same industry are doing better.
A Quick Ratio of 1.26 indicates that BDRX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.26, BDRX is doing worse than 84.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
BDRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.55%, which is quite impressive.
The Revenue for BDRX has decreased by -45.49% in the past year. This is quite bad
Measured over the past years, BDRX shows a small growth in Revenue. The Revenue has been growing by 3.56% on average per year.
EPS 1Y (TTM)98.55%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q98.8%
Revenue 1Y (TTM)-45.49%
Revenue growth 3Y3.56%
Revenue growth 5YN/A
Revenue growth Q2Q-64.07%
3.2 Future
The Earnings Per Share is expected to grow by 16.56% on average over the next years. This is quite good.
Based on estimates for the next years, BDRX will show a very negative growth in Revenue. The Revenue will decrease by -18.92% on average per year.
EPS Next Y99.79%
EPS Next 2Y41.36%
EPS Next 3Y22.67%
EPS Next 5Y16.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BDRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BDRX's earnings are expected to grow with 22.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3Y22.67%
5. Dividend
5.1 Amount
No dividends for BDRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIODEXA PHARMACEUTICALS-ADR
NASDAQ:BDRX (5/15/2024, 1:45:26 PM)
1.11
+0.01 (+0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.87M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.15% | ||
| ROE | -151.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)98.55%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y99.79%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-45.49%
Revenue growth 3Y3.56%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y